Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Samol

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Human Genomics|August 14, 2023
Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancerNing-Yuan Lee, Melissa Hum, Sabna Zihara, et al.
Human Genomics|July 17, 2023
Landscape of germline pathogenic variants in patients with dual primary breast and lung cancerNing-Yuan Lee, Melissa Hum, Sabna Zihara, et al.
NPJ Precision Oncology|November 13, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian populationJing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2025
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 TrialDavid Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, et al.
Clinical Lung Cancer|March 27, 2025
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case SeriesXiuning Le, Anna Eisert, Te-Chun Hsia, et al.
The Lancet. Oncology|January 18, 2025
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trialWan-Qin Chong, Jia-Li Low, Joshua K Tay, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Nature Medicine|January 14, 2022
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Human Genomics|August 14, 2023
Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancerNing-Yuan Lee, Melissa Hum, Sabna Zihara, et al.
Human Genomics|July 17, 2023
Landscape of germline pathogenic variants in patients with dual primary breast and lung cancerNing-Yuan Lee, Melissa Hum, Sabna Zihara, et al.
NPJ Precision Oncology|November 13, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian populationJing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2025
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 TrialDavid Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, et al.
Clinical Lung Cancer|March 27, 2025
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case SeriesXiuning Le, Anna Eisert, Te-Chun Hsia, et al.
The Lancet. Oncology|January 18, 2025
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trialWan-Qin Chong, Jia-Li Low, Joshua K Tay, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Nature Medicine|January 14, 2022
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Pageof 4